Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4822831 | 0.89 | OPRD1 (0.55) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL4827779 | 0.88 | OPRD1 (0.53) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL1996254 | 0.87 | OPRD1 (0.60) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL12569805 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2 | |
| SCHEMBL12569804 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2 | |
| SCHEMBL2001487 | 0.86 | OPRD1 (0.72) | OPRD1OPRM1KCNH2 | |
| SCHEMBL231375 | 0.85 | OPRD1 (0.67) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL15764535 | 0.85 | OPRD1 (0.67) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6245607 | 0.84 | OPRD1 (0.55) | OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6236576 | 0.84 | OPRD1 (0.58) | OPRD1OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278740-B1 | HYDROXYPHENYL-PIPERAZINYL-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | claimed |
| US-6696447-B2 | ANALGESICS; GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2004-02-24 | — | — | US | claimed |
| US-20030139421-A1 | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | claimed |
| CN-1422266-A | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-06-04 | — | — | CN | claimed |
| EP-1278740-A1 | HYDROXYPHENYL-PIPERAZINYL-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001074805-A1 | HYDROXYPHENYL-PIPERAZINYL-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | claimed |
| EP-1278740-B1 | HYDROXYPHENYL-PIPERAZINYL-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-6696447-B2 | ANALGESICS; GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2004-02-24 | — | — | US | disclosed |
| US-20030139421-A1 | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| CN-1422266-A | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2003-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139421-A1 | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | OPRM1, OPRK1, PTGER1 | OPRD1 10/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.